Services
Our team of experienced scientists and biologists provides comprehensive end-to-end support for your experiments-from disease modelling to safety and efficacy testing. We guide you through every step, including experimental design, execution, data analysis, and final reporting.
- Custom-built models
- High quality biological and regulatory insight
- Full-service in-house execution
Build your model
Tissue
Select your organ of interest fitting to your study.
We create physiologically accurate models of a wide range of barrier tissues – including lung, gut, bladder, kidney, and more – customized to your specific needs. Through close collaboration with biobanks worldwide, we can source precise tissue types and donor profiles (from pediatric to adult, including disease-specific samples) to ensure your study objectives align with clinical relevance.
Cells
We offer a diverse selection of highly customizable cell sources.
Primary Cells: HLA- and donor-matched available | Pediatric, elderly, pregnant, and disease specific donors | Clinical background available on request
Immortalized: Robustness | Reproducibility | Standardization | Including our proprietary human alveolar epithelial cell line with strong TER formation
Organoids: Patient-derived, tissue-specific 3D models | Maintain phenotypic fidelity and offer high throughput compatibility
Complexity
Several culture options reflecting the needed complexity.
With AlveoliX, you define the level of innovation for your research – from classic cell culture plates to advanced cell culture inserts and state-of-the-art organ-on-chip systems. We offer flexibility across complexity factors – ensuring your model matches your scientific objective:
- Mono-, Co-, or Multi-culture systems
- Air-liquid interface or submerged
- Immune competent cultures
- Static or dynamic conditions
Substance Type and Modality
Compatibility and experience with different substances.
The model needs to be fine-tuned according to your specific molecule or compound and the objectives of your project. Our expertise spans a variety of areas, including:
- Small molecules
- Antibodies, proteins, and bioconjugates
- Nucleic acid-based therapeutics
- Nanomaterials and nanoparticles
- Drug delivery systems
- Excipients and formulation components
In partnership with Alexis and VitroCell, we provide various administration methods such as submerged exposure, nebulization, and dry powder delivery.
Readouts
TEER and impedance spectroscopy evaluate barrier function and cell layer integrity. The AX12 chip simplifies such measurements. When measured with the AXTEEROC, the outcome is fully automated, robust, and reproducible saving valuable time for barrier integrity assessment.
Cell viability and toxicity assays determine the health, metabolic activity, and potential cytotoxic responses of cells. On the AX12 chip, these assays can be carried out using standard dyes and reagents by luminescent/fluorescent readouts, enabling straightforward evaluation of cell integrity for reliable in vitro viability or toxicity screening.
Permeability assay quantifies passive diffusion and/or active transport of a molecule across cellular and tissue barriers and allows to study drug delivery , uptake and transport, supporting in vitro ADME and PK testing. The AX12 chip’s configuration enables simple sampling from both apical and basolateral chambers, allowing precise evaluation of compound transport dynamics under controlled conditions.
Live‑cell imaging on chip enables real‑time assessment of cell morphology, cytotoxicity, and drug uptake throughout the experiment. Thanks to the AX12 chip configuration, a wide range of imaging modalities can be applied, from low‑ to high‑magnification imaging, to visualize cell morphology, tight junction formation, and cell‑specific protein markers.
Cells can be harvested directly from the chip and analyzed by flow cytometry to quantify targeted protein expression, assess cellular phenotypes, and evaluate treatment‑induced changes. This approach supports detailed analysis of immune cell differentiation, activation, and phenotypic shifts within a controlled microphysiological environment.
Targeted gene expression readouts, such as RT‑qPCR, enable analysis of selected disease, inflammatory, or receptor genes under physiological conditions or following compound exposure. On the AX12 chip, gene expression can be measured from defined cell populations, allowing focused pathway analysis, target validation, and mechanism‑of‑action studies. These targeted approaches provide biologically meaningful insights without the complexity of full Omics workflows.
Targeted protein and cytokine secretion can be quantified from apical and basolateral compartments using ELISA or customized cytokines panels, enabling detection of disease‑relevant or inflammatory biomarkers. These targeted approaches provide biologically meaningful insights without the complexity of full Omics workflows.
Multi‑omics workflow integration allows comprehensive profiling of cellular responses, integrating transcriptomic, proteomic, and metabolomic analyses. Samples collected from the AX12 chip are fully compatible with, and validated for advanced omics pipelines, enabling deep molecular characterization of barrier tissue models.
Applications
Our platform creates customizable in vitro models-healthy, diseased, or personalized-to study safety, efficacy, and toxicity of drugs, pollutants, cosmetics, nutrient supplements and biologics. It offers high-resolution insights into compound effects on tissue barriers, immune infiltration, and integrity, while enabling fundamental research into cell communication, mechanical stress, and immune interactions. The AXBarrier-on-Chip serves as both a testing platform and a discovery engine for applied biosciences.
Our Case Studies
Leveraging the deep expertise of our lung specialists, our Lung‑on‑Chip models accurately replicate key regions of the lung—including the alveolar barrier and bronchial airways. They are available in different levels of complexity (from mono‑ to triple‑culture systems, including air–liquid interface models and breathing like motion) and can be generated using primary cells or cell lines. These models are well suited for both safety assessment and efficacy testing.
Link:
Breathing Lung-on-Chip: a versatile tool for assessing respiratory toxicity across multiple therapeutic modalities | Archives of Toxicology | Springer Nature Link A stretchable human Lung-on-Chip model of alveolar inflammation for evaluating anti-inflammatory drug response | Bioengineering & translational medicine Patient derived AXLung-on-Chip model for immunotherapy safety: a case study with T-Cell bispecific antibodies (TCBs) | AlveoliX Patient derived AXLung-on-Chip model: mimicking Interleukin-2 – induced vascular leak syndrome and patient-specific responses | AlveoliX
Our gut-on-chip model, based on human primary cells or cell lines, exhibits robust barrier integrity and incorporates key epithelial subtypes to create a physiologically relevant system under peristalsis. This platform offers a reliable solution for evaluating compound and nutrient efficacy, as well as gastrointestinal toxicity in response to oral drugs and biologics.
Renal proximal tubular epithelial cells (RPTECs) are cultured on‑chip to reproduce the structure and functionality of the proximal tubule, creating a simple yet sufficiently complex model capable of evaluating compound‑induced nephrotoxicity and studying excretion processes and dynamics related to ADME.
Our interstitial lung disease model, composed of donor-derived epithelial cells and lung fibroblasts, demonstrates key fibrotic markers, with efficacy testing validated using the FDA-approved drug nintedanib. In addition, our proprietary epithelial cell line, when combined with lung fibroblasts and fibrotic inducer, exhibits characteristic fibrotic hallmarks. Both models provide robust platforms for evaluating anti-fibrotic compound efficacy and assessing safety related to fibrotic risk.
Our Gut-on-Chip models recreate key inflammatory processes underlying Crohn’s disease and ulcerative colitis by integrating human intestinal epithelial co‑cultures with physiologically relevant biomechanical cues. Exposing epithelial cells to controlled pro‑inflammatory cytokine cocktails, the Gut‑on‑Chip platform enables the induction of a ‘leaky‑gut’ phenotype characterized by barrier disruption, altered epithelial differentiation, increased cytokine release, and immune‑modulated responses. The incorporation of rhythmic, peristalsis‑like mechanical stretch enhances model sensitivity to inflammatory triggers and more accurately reflects in vivo intestinal dynamics.
Our COPD models recreate key physiological features of the diseased lung, enabling controlled and reproducible investigation of chronic obstructive pulmonary disease mechanisms. Using human alveolar and airway cell types cultured under air–liquid interface and breathing‑like mechanical stretch, these Lung‑on‑Chip systems allow the study of inflammatory responses, barrier dysfunction, oxidative stress, and tissue remodeling characteristic of COPD.
Link:
Alexis Technologies
Our infection models allow the study of both viral (e.g. SARS-CoV-s, influenza) and bacterial pathogens (e.g. S. pneumoniae, E. coli) under physiologically relevant conditions. These models support a wide range of functional readouts reflecting native tissue responses—such as barrier integrity, cytokine release, pathogen replication dynamics, and host–pathogen interactions. Moreover, the models can be operated within BSL‑3 facilities, enabling the safe handling of high‑risk infectious agents while preserving experimental fidelity.
Our pulmonary hypertension model, developed using alveolar endothelial and/or epithelial cells, replicates key pathological features such as increased vascular permeability (indicated by reduced TEER) and elevated inflammatory markers. This physiologically relevant platform is suitable for efficacy testing of therapeutic candidates.
Link:
Alexis Technologies
Interested in our custom models?
Do you need regulatory support?
